IQE Takeout?

March 2026 | ~19p | Market Cap ~£190m ($240m) | ~978m shares outstanding 52-Week Range: 4.7p – 21.8p | FY2025 Revenue: ~£97m

Executive Summary

IQE is the world's leading pure-play outsourced epitaxial wafer manufacturer for compound semiconductors. The company sits at one of the most technically demanding and strategically critical steps in the semiconductor supply chain — growing atomically precise crystalline layers that define the performance of every VCSEL, laser, power amplifier, and infrared detector used in smartphones, data centres, military systems, and next-generation displays.

Despite owning genuinely scarce technology in a market growing at double-digit rates, IQE trades at a deeply distressed valuation (~2x trough-cycle revenue) due to balance sheet constraints, serial revenue declines, and an unresolved strategic review. The company is currently in an offer period under the UK Takeover Code, with the board negotiating non-binding offers for the group as a whole and for individual assets.

The Science — What IQE Actually Does

Supply Chain Position

Raw substrate → Epitaxial growth (IQE) → Wafer fabrication → Chip packaging → Device/OEM

IQE takes blank compound semiconductor substrates and deposits ultra-precise, atom-by-atom crystalline layers on top. These epitaxial layers are what actually define the device's electronic and photonic performance. The epi layer accounts for up to 80% of a device's value, depending on the application.

The analogy: If TSMC is the foundry that makes chips designed by fabless companies, IQE is effectively the "TSMC of compound semiconductor epitaxy" — but at a much earlier, more materials-science-intensive stage. They grow the crystalline layers; their customers then process those wafers into actual devices.

Why Compound Semiconductors Matter

Silicon dominates most computing, but it is fundamentally poor at three things: emitting and detecting light, operating at very high frequencies, and handling high power efficiently. Compound semiconductors — made from combining elements from groups III and V of the periodic table (hence "III-V") — are the materials that do all of these. Every laser in a data centre, every VCSEL in a smartphone face scanner, every power amplifier in a 5G radio, and every infrared detector in a military system uses III-V materials.

IQE's Four Material Families

• GaAs (Gallium Arsenide) — The workhorse. Used in smartphone power amplifiers for RF/wireless (IQE's legacy cash-generating business) and in VCSELs for 3D sensing (Face ID-style facial recognition). GaAs RF is a mature, ~90% outsourced market
• InP (Indium Phosphide) — The AI/data centre play. InP lasers and photodetectors are the backbone of optical interconnects inside data centres — the fibre-optic transceivers shuttling data between servers at 400G/800G speeds. As AI training clusters scale, demand for higher-bandwidth optical interconnects is growing rapidly
• GaN (Gallium Nitride) — The next-generation RF and power play. GaN delivers far higher power density than GaAs, making it essential for 5G base station infrastructure, military radar, and increasingly power electronics for EVs and industrial applications. For GaN, the epitaxy is the device — it's where the value sits
• GaSb (Gallium Antimonide) — Niche but strategically important. Used in infrared imaging and sensing for military/defence — night vision, target detection, HAZMAT identification

The Two Growth Technologies

• MOCVD (Metal Organic Chemical Vapour Deposition) — The high-throughput production workhorse. Chemical precursors are flowed over heated substrates in a reactor, decomposing and depositing atomically precise layers. Used for the majority of commercial GaAs, InP, and GaN production
• MBE (Molecular Beam Epitaxy) — Slower but offers even finer control. Used for R&D and specialised military/infrared applications where defect tolerance is extremely low

IQE is the only company with mass production capability in both epitaxial growth technologies for III-V compound semiconductors.

Why Epitaxy Is Hard

Growing crystals one atomic layer at a time. The composition, thickness, doping profile, and defect density of each layer must be controlled to extraordinary precision — getting the right number of atoms in each monolayer across an entire 6-inch or 8-inch wafer. A single defect in a VCSEL layer stack can kill the laser. This is why there are so few scaled outsourced epi providers globally.

A Concrete Example

Apple needs 3D face sensing → Apple contracts Lumentum to design/supply VCSEL arrays → Lumentum uses IQE and WIN Semiconductors for epiwafer manufacturing → Lumentum processes the epiwafers into VCSEL dies → packaged and integrated into the iPhone. IQE is two or three steps removed from the end consumer — insulation from brand risk, but vulnerability to inventory cycles.

Competitive Positioning

IQE is differentiated because it is the only pure-play epi-wafer producer with the entire portfolio of III-V materials AND global manufacturing across the three key regions: US, EU-UK, and Asia. This means IQE can serve a US defence customer needing GaSb infrared wafers from a CONUS facility, a European telecom needing InP, and an Asian smartphone supply chain needing GaAs VCSELs from Taiwan — all from one supplier.

Key Competitors

Moat Assessment

The moat is real but under pressure. Breadth across all four material systems, dual deposition technologies, and US/UK/Taiwan geographic spread are genuine differentiators. The US and UK presence is particularly valuable for defence/security-cleared applications where ITAR compliance and supply chain sovereignty matter. However, in commoditised GaAs RF wireless, they've been steadily losing share to lower-cost Asian suppliers.

Current Financials

FY2025 Results

• Revenue at upper end of £90-100m guidance, but still down 18% YoY and 37% from 2021 peak
• H1 was ugly: £45.3m revenue, wireless down 52% on inventory destocking, handset softness, and tariff uncertainty
• H2 recovered on accelerated US defence funding, stronger AI/data centre photonics demand, and new handset introductions in Taiwan
• Balance sheet is the binding constraint: £15.6m cash is thin. HSBC revolving credit facility needed a Q3 covenant waiver. Convertible loan notes issued in March 2025 add debt and dilution risk

The Strategic Review

This is the dominant near-term catalyst. The board (advised by Lazard) is negotiating non-binding offers for the Group as a whole plus separate bids for certain other Group assets, aiming to maximise shareholder value. IQE is progressing negotiations with multiple parties for the sale of Taiwan operations, which would repay the revolving credit facility and convertible notes while providing cash for core operations.

The company has been in an "offer period" under the UK Takeover Code since September 2025. Shares surged 20% in late February 2026 on takeover-code filings from Deutsche Bank, Peel Hunt, and River Global. However, no formal bid has been announced and there is no certainty any deal materialises.

IQE enters 2026 with a strong Q1 order book reflecting improved visibility across consumer mobile, data centre, and AI-related photonics.

Trading Comparables

No direct public peer exists — IQE is the only listed pure-play outsourced III-V epitaxy company. Comps must be drawn from adjacent supply chain layers.

What the Multiples Reveal

The spread is enormous and tells you exactly where the market assigns the AI/photonics premium.

Lumentum has rerated dramatically — up ~125% since September 2025 as AI data centre optical demand exploded. Record revenue of $665.5m in fiscal Q2 2026, up 65.5% YoY. Guiding for $630-670m quarterly. Expanding InP wafer fab capacity across Japan, UK, and new sites. Lumentum is one of IQE's biggest customers for VCSEL epiwafers. The fact that Lumentum trades at 20x+ revenue while its key upstream supplier trades at 2x tells you the market prices zero AI photonics premium into IQE.

Coherent at ~7.5x revenue captures a vertical integration premium. Their Materials segment alone (epitaxy, substrates, VCSELs — the segment most comparable to IQE) does ~$1.5B+ in revenue.

WIN Semi at 6-7x is the closest structural comp but operates at the fab level, not epi. Trades at a substantial premium to IQE despite operating in an arguably less differentiated part of the value chain.

Wolfspeed at ~2x is the interesting structural parallel — also substrate/epi-level with heavy fixed costs. Both demonstrate that being early in the supply chain with high operational leverage results in brutal valuations when utilisation is low.

Implied Valuation Scenarios

Historical III-V M&A: Coherent/II-VI at ~4.5x revenue, Lumentum/NeoPhotonics at ~3x revenue.

Why the Discount Is So Large

1. Balance sheet risk: £15.6m cash, covenant waivers, convertible debt. The market prices in a dilutive raise or fire sale
2. Inferior margins: Gross margins of 30-35% vs. WIN (~35%), Coherent Materials (~38%), Lumentum (~40%+). Reflects chronic underutilisation — epi is a high-fixed-cost business where utilisation rate drives everything
3. Serial revenue decline: £178m (2020) → £154m (2021) → £118m (2024) → £97m (2025). Multiple "next year will be better" cycles have destroyed credibility
4. AIM-listed micro-cap: Limited institutional coverage. Many global semi investors can't or won't hold an AIM stock at this market cap. Thin liquidity creates forced-seller dynamics
5. Geographic/structural complexity: UK, US, Taiwan operations with different cost structures. Potential Taiwan sale adds uncertainty about what the remaining entity looks like

The Bull Case

AI/Data Centre Photonics (InP) — The Killer App

Every AI training cluster and inference farm needs massive optical interconnect bandwidth. As data centres transition from 400G to 800G to 1.6T transceivers, InP laser and photodetector demand scales proportionally. Hyperscalers (Google, Microsoft, Amazon, Meta) are spending $200B+ annually on AI capex — a meaningful portion flows through the optical interconnect supply chain. IQE's InP epi capability directly benefits. Management reported strong organic growth in InP for data centre and optical markets in H2 2025.

Next-Gen Smartphone VCSELs (GaAs)

The smartphone market is cyclically weak, but content per phone is increasing. Behind-OLED (BOLED) proximity sensors, longer-wavelength VCSELs for enhanced 3D sensing, and potential AR features drive epiwafer complexity and ASP. IQE's VCSEL-on-Germanium technology enabling integration with CMOS on 200mm substrates could be transformative — it would allow compound semiconductor photonics to run in existing silicon fabs.

GaN for RF and Power

5G/6G base station densification requires GaN power amplifiers. Military radar modernisation is a secular driver. GaN power electronics for EVs and industrial are earlier stage but growing rapidly. IQE has 20+ years of GaN-on-SiC history and is developing GaN-on-Si for lower-cost, high-volume applications.

MicroLED Displays — Potentially the Biggest Volume Driver

MicroLED is expected to power next-generation AR/VR headsets (Apple Vision Pro successors, Meta's AR glasses). IQE's CTO has stated that "in my view microLEDs will be the biggest pull for eight inch volume for compound semiconductors — then this will enable everything else." IQE has partnered with Porotech to commercialise GaN-based microLEDs.

Defence/Aerospace

GaSb infrared detectors and InP quantum cascade lasers for military sensing are high-margin, long-cycle programmes. IQE's US and UK manufacturing gives it preferred supplier status for classified programmes. Deferred US defence funding is now flowing into 2026.

Market Growth Context

The compound semiconductor substrate and open epiwafer markets are projected to reach ~$5.2B by 2031 (14% CAGR). The open epiwafer market alone should hit $2.5B by 2029 (19% CAGR). IQE is the scaled Western pure-play — that has strategic value to a Coherent, a Broadcom, a defence prime, or potentially even sovereign/national security buyers given UK/US semiconductor policy.

The Bear Case

• Balance sheet is precarious: £15.6m cash with covenant pressure. A dilutive capital raise or fire sale at a low premium could destroy shareholder value
• Revenue concentration: Historically over-exposed to cyclical handset/VCSEL demand, with a single major customer (widely believed to be the Apple/Lumentum supply chain) driving disproportionate revenue
• Taiwan asset sale risk: Could leave a smaller, less diversified company with higher per-unit fixed costs
• Chinese competition: Mainland Chinese epi houses are scaling capacity, particularly in GaAs RF, threatening IQE's share in commoditised segments
• Serial execution disappointment: The stock has been a value trap for years, with management repeatedly promising inflection points that didn't materialise. The bull case requires either a takeout or management finally demonstrating operating leverage
• Takeover code constraints: The offer period restricts management from communicating fully, creating information asymmetry
• Margin problem is structural at current volumes: Epi is a high-fixed-cost business. Until utilisation rates improve materially, margins will remain compressed vs. peers

The Bottom Line

IQE owns genuinely scarce, strategically critical technology in a market growing at double-digit rates. It's the only global pure-play outsourced epitaxy provider spanning all four III-V material families, both deposition technologies, and three geographic regions.

At ~2x trough-cycle revenue, the stock prices in significant distress relative to peers at 5-20x. Comparable transaction analysis suggests 3-4x revenue is a reasonable takeout range, implying 30-40p per share (55-110% upside). On a normalised revenue base with market recovery, the equity could be worth considerably more.

The critical question is whether shareholders get to participate in the upside, or whether the balance sheet forces a takeout at a modest premium that mostly benefits the acquirer. The strategic review resolution is the key near-term catalyst, with the operational recovery in AI photonics and defence providing the fundamental underpinning.

If a credible bidder emerges at 3-4x revenue, this is a double from here. If the strategic review fizzles and IQE has to raise equity at 19p, the value trap continues. The setup is high-conviction directionally but binary on the corporate outcome.

Key Dates to Watch

• Strategic review resolution — The dominant catalyst. Any formal bid announcement or Taiwan sale completion changes the equity story entirely
• FY2025 full results — Detailed financials, cash flow, and forward guidance
• Q1/Q2 2026 trading updates — Will confirm whether the AI photonics and defence recovery has legs
• Lumentum capacity expansion updates — As IQE's key customer scales InP demand, read-through to IQE volumes
• UK/US semiconductor policy developments — CHIPS Act equivalents and supply chain sovereignty initiatives could provide strategic tailwinds or even direct subsidies